Allergen specific immunotherapy controls the reaction and builds immunological tolerance by giving an allergen in escalating doses. Research on immunotherapy in atopic dermatitis (AD) mouse model offers a new perspective on the approach of treatment in AD. This was an experimental study of 33 male BALB/c mice, 6-8 weeks old, divided into 3 groups (control, AD model, and house dust mite/HDM immunotherapy). The mice received spray and patch containing allergen extract of Dermatophagoides pteronyssinus. Immunotherapy was injected subcutaneously in increasing doses. The evaluation of SCORAD and scratching behavior were observed at the end of the treatment on day 93. The SCORAD of the model group that received HDM allergen had a mean of 1.27 ± 0.467 and the immunotherapy group had a mean of 0.36 ± 0.505. There were significant differences between the groups. The model group had a mean of 5.18 ± 4.119 and the immunotherapy group had mean of 1.55 ± 1.293. The statistical analysis showed that there were significant differences between control group and model group, as well as model group and immunotherapy group. Interobserver agreement was assessed and showed substantial agreement for SCORAD (ĸ = 0.613 and p < 0.001) and scratching evaluation (ĸ = 0.714 and p < 0.001). House dust mite immunotherapy significantly reduced SCORAD and scratching behavior in BALB/c mice compared to placebo groups.

Original languageEnglish
Pages (from-to)121-129
Number of pages9
JournalVeterinary Integrative Sciences
Issue number1
Publication statusPublished - 1 Jan 2024


  • Atopic dermatitis
  • BALB/c mice
  • House dust mites
  • Immunotherapy
  • Tropical disease


Dive into the research topics of 'Evaluation of scoring atopic dermatitis (SCORAD) and scratching behavior in BALB/c mice treated with house dust mite immunotherapy'. Together they form a unique fingerprint.

Cite this